2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia and myelodysplastic syndrome.
Eytan Stein, MD, attending physician in the leukemia service at Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia (AML) and myelodysplastic syndrome.
At the time of the data cut-off, 45 patients with IDH2 mutations were analyzed for response. Overall, by investigator-accessed criteria, 56% of patients responded to therapy, Stein explained.
Responses were comprised of complete remissions (CR; n = 6), CR with incomplete platelet recovery (n = 4), marrow CR (n = 4), CR with incomplete hematologic recovery (n = 1), and partial remissions (n = 10). Responses were durable and lasted for 3 months or longer in the majority of patients.
These findings were from an interim analysis of a phase I trial, Stein emphasized. However, if these results are confirmed in larger trials, it could represent a quantum leap over previous treatments for patients with AML that could potentially lead to durable remissions.
<<<
Related Content: